{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T11:51:34Z","timestamp":1792756294695,"version":"4.5.0"},"reference-count":55,"publisher":"Harborside Press, LLC","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:p>Marginal zone lymphoma (MZL) is the third most common B-cell non-Hodgkin lymphoma and tends to follow the relapsing course typical of other indolent lymphomas, meaning that many patients receive multiple lines of therapy. Br\u00fcton\u2019s tyrosine kinase inhibitors (BTKis) have been a promising addition to the treatment landscape of relapsed MZL; however, development of resistance to these agents remains a significant problem that warrants further characterization. This case report presents a patient with relapsed MZL receiving the BTKi zanubrutinib who experienced large cell transformation of their lymphoma in concert with the development of mutations predictive of resistance to BTKi therapy, specifically <jats:italic>BTK<\/jats:italic> C481S and <jats:italic>PLCG2<\/jats:italic> D334H. To our knowledge, this is the first reported case of a patient with MZL acquiring co-mutations in <jats:italic>BTK<\/jats:italic> and <jats:italic>PLCG2<\/jats:italic> in concert with the development of disease progression while receiving BTKi therapy. Outcomes for patients with MZL who develop resistance to BTKis have not been fully characterized, but are poor in other B-cell malignancies that have acquired BTKi resistance, such as mantle cell lymphoma and chronic lymphocytic leukemia. Improved understanding of the genetic and molecular drivers of MZL is leading to new treatment strategies. Further studies of novel therapeutic approaches are ongoing to improve outcomes for patients with MZL, including those who acquire resistance to BTKis.<\/jats:p>","DOI":"10.6004\/jnccn.2025.7045","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T10:30:21Z","timestamp":1750674621000},"source":"Crossref","is-referenced-by-count":3,"title":["Resistance Mechanism for Zanubrutinib in Marginal Zone Lymphoma"],"prefix":"10.6004","volume":"23","author":[{"given":"John","family":"Sharp","sequence":"first","affiliation":[{"name":"Division of Hematology, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arwa Y.","family":"Shana\u2019ah","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Voorhees","sequence":"additional","affiliation":[{"name":"Division of Hematology, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Bond","sequence":"additional","affiliation":[{"name":"Division of Hematology, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazeed","family":"Sawalha","sequence":"additional","affiliation":[{"name":"Division of Hematology, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Sigmund","sequence":"additional","affiliation":[{"name":"Division of Hematology, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Hanel","sequence":"additional","affiliation":[{"name":"Division of Hematology, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lalit","family":"Sehgal","sequence":"additional","affiliation":[{"name":"Division of Hematology, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lapo","family":"Alinari","sequence":"additional","affiliation":[{"name":"Division of Hematology, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Baiocchi","sequence":"additional","affiliation":[{"name":"Division of Hematology, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kami","family":"Maddocks","sequence":"additional","affiliation":[{"name":"Division of Hematology, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Jones","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Christian","sequence":"additional","affiliation":[{"name":"Division of Hematology, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narendranath","family":"Epperla","sequence":"additional","affiliation":[{"name":"Division of Hematology, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH"},{"name":"Division of Hematology and Hematologic Malignancies, Department of Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","series-title":"Clin Cancer Res","first-page":"6323","article-title":"The MAGNOLIA trial: zanubrutinib, a next-generation Bruton tyrosine kinase inhibitor, demonstrates safety and efficacy in relapsed\/refractory marginal zone lymphoma","volume":"27","author":"Opat S","year":"2021","unstructured":"Opat S, Tedeschi A, Linton K,  The MAGNOLIA trial: zanubrutinib, a next-generation Bruton tyrosine kinase inhibitor, demonstrates safety and efficacy in relapsed\/refractory marginal zone lymphoma. Clin Cancer Res 2021;27:6323\u20136332."},{"key":"B2","series-title":"Blood Adv","first-page":"6801","article-title":"Safety and efficacy of zanubrutinib in relapsed\/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study","volume":"7","author":"Opat S","year":"2023","unstructured":"Opat S, Tedeschi A, Hu B,  Safety and efficacy of zanubrutinib in relapsed\/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study. Blood Adv 2023;7:6801\u20136811."},{"key":"B3","series-title":"Blood Adv","first-page":"3472","article-title":"Zanubrutinib monotherapy in relapsed\/refractory indolent non-Hodgkin lymphoma","volume":"6","author":"Phillips T","year":"2022","unstructured":"Phillips T, Chan H, Tam CS,  Zanubrutinib monotherapy in relapsed\/refractory indolent non-Hodgkin lymphoma. Blood Adv 2022;6:3472\u20133479."},{"key":"B4","series-title":"N Engl J Med","first-page":"2286","article-title":"Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach JA","year":"2014","unstructured":"Woyach JA, Furman RR, Liu TM,  Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib. N Engl J Med 2014;370:2286\u20132294."},{"key":"B5","series-title":"Blood","first-page":"471","article-title":"Targeted therapies in CLL: mechanisms of resistance and strategies for management","volume":"126","author":"Woyach JA","year":"2015","unstructured":"Woyach JA, Johnson AJ. Targeted therapies in CLL: mechanisms of resistance and strategies for management. Blood 2015;126:471\u2013477."},{"key":"B6","series-title":"J Clin Oncol","first-page":"1198","article-title":"Genomic landscape of Waldenstr\u00f6m macroglobulinemia and its impact on treatment strategies","volume":"38","author":"Treon SP","year":"2020","unstructured":"Treon SP, Xu L, Guerrera ML,  Genomic landscape of Waldenstr\u00f6m macroglobulinemia and its impact on treatment strategies. J Clin Oncol 2020;38:1198\u20131208."},{"key":"B7","series-title":"Cancer Discov","first-page":"1022","article-title":"Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma","volume":"4","author":"Chiron D","year":"2014","unstructured":"Chiron D, Di Liberto M, Martin P,  Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma. Cancer Discov 2014;4:1022\u20131035."},{"key":"B8","series-title":"Blood Adv","first-page":"500","article-title":"Resistance mechanism for ibrutinib in marginal zone lymphoma","volume":"3","author":"Epperla N","year":"2019","unstructured":"Epperla N, Shana\u2019ah AY, Jones D,  Resistance mechanism for ibrutinib in marginal zone lymphoma. Blood Adv 2019;3:500\u2013502."},{"key":"B9","series-title":"Blood","first-page":"170","article-title":"BTK Leu528Trp - a potential secondary resistance mechanism specific for patients with chronic lymphocytic leukemia treated with the next generation BTK inhibitor zanubrutinib","volume":"134","author":"Handunnetti SM","year":"2019","unstructured":"Handunnetti SM, Tang CPS, Nguyen T,  BTK Leu528Trp - a potential secondary resistance mechanism specific for patients with chronic lymphocytic leukemia treated with the next generation BTK inhibitor zanubrutinib. Blood 2019;134(Suppl 1):170."},{"key":"B10","series-title":"Blood Adv","first-page":"5589","article-title":"Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance","volume":"6","author":"Blombery P","year":"2022","unstructured":"Blombery P, Thompson ER, Lew TE,  Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance. Blood Adv 2022;6:5589\u20135592."},{"key":"B11","series-title":"Br J Haematol","first-page":"62","article-title":"A two-part, single-arm, multicentre, phase I study of zanubrutinib, a selective Bruton tyrosine kinase inhibitor, in Chinese patients with relapsed\/refractory B-cell malignancies","volume":"198","author":"Song Y","year":"2022","unstructured":"Song Y, Sun M, Qi J,  A two-part, single-arm, multicentre, phase I study of zanubrutinib, a selective Bruton tyrosine kinase inhibitor, in Chinese patients with relapsed\/refractory B-cell malignancies. Br J Haematol 2022;198:62\u201372."},{"key":"B12","series-title":"Blood Cancer J","first-page":"182","article-title":"Evaluation of Ki-67 expression and large cell content as prognostic markers in MZL: a multicenter cohort study","volume":"14","author":"Grover NS","year":"2024","unstructured":"Grover NS, Annunzio K, Watkins M,  Evaluation of Ki-67 expression and large cell content as prognostic markers in MZL: a multicenter cohort study. Blood Cancer J 2024;14:182."},{"key":"B13","series-title":"Am J Hematol","first-page":"790","article-title":"Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: a longitudinal analysis of the National Cancer Data Base from 1998 to 2011","volume":"90","author":"Al-Hamadani M","year":"2015","unstructured":"Al-Hamadani M, Habermann TM, Cerhan JR,  Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: a longitudinal analysis of the National Cancer Data Base from 1998 to 2011. Am J Hematol 2015;90:790\u2013795."},{"key":"B14","series-title":"Blood","first-page":"2375","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow SH","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA,  The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016;127:2375\u20132390."},{"key":"B15","series-title":"Molecules","first-page":"2400","article-title":"Bruton\u2019s tyrosine kinase inhibitors (BTKIs): review of preclinical studies and evaluation of clinical trials","volume":"28","author":"Rozkiewicz D","year":"2023","unstructured":"Rozkiewicz D, Hermanowicz JM, Kwiatkowska I,  Bruton\u2019s tyrosine kinase inhibitors (BTKIs): review of preclinical studies and evaluation of clinical trials. Molecules 2023;28:2400."},{"key":"B16","series-title":"Eur J Med Chem","first-page":"113329","article-title":"Emerging small-molecule inhibitors of the Bruton\u2019s tyrosine kinase (BTK): current development","volume":"217","author":"Liu J","year":"2021","unstructured":"Liu J, Chen C, Wang D,  Emerging small-molecule inhibitors of the Bruton\u2019s tyrosine kinase (BTK): current development. Eur J Med Chem 2021;217:113329."},{"key":"B17","series-title":"Front Immunol","first-page":"662223","article-title":"Bruton\u2019s tyrosine kinase (BTK) inhibitors and autoimmune diseases: making sense of BTK inhibitor specificity profiles and recent clinical trial successes and failures","volume":"12","author":"Ringheim GE","year":"2021","unstructured":"Ringheim GE, Wampole M, Oberoi K. Bruton\u2019s tyrosine kinase (BTK) inhibitors and autoimmune diseases: making sense of BTK inhibitor specificity profiles and recent clinical trial successes and failures. Front Immunol 2021;12:662223."},{"key":"B18","series-title":"Proc Natl Acad Sci U S A","first-page":"9390","article-title":"Structural mechanism for Bruton\u2019s tyrosine kinase activation at the cell membrane","volume":"116","author":"Wang Q","year":"2019","unstructured":"Wang Q, Pechersky Y, Sagawa S,  Structural mechanism for Bruton\u2019s tyrosine kinase activation at the cell membrane. Proc Natl Acad Sci U S A 2019;116:9390\u20139399."},{"key":"B19","series-title":"Leukemia","first-page":"312","article-title":"Inhibitors targeting Bruton\u2019s tyrosine kinase in cancers: drug development advances","volume":"35","author":"Wen T","year":"2021","unstructured":"Wen T, Wang J, Shi Y,  Inhibitors targeting Bruton\u2019s tyrosine kinase in cancers: drug development advances. Leukemia 2021;35:312\u2013332."},{"key":"B20","series-title":"N Engl J Med","first-page":"2425","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger JA","year":"2015","unstructured":"Burger JA, Tedeschi A, Barr PM,  Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med 2015;373:2425\u20132437."},{"key":"B21","series-title":"N Engl J Med","first-page":"319","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown JR","year":"2023","unstructured":"Brown JR, Eichhorst B, Hillmen P,  Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med 2023;388:319\u2013332."},{"key":"B22","series-title":"Hemasphere","first-page":"e801","article-title":"Acalabrutinib versus investigator\u2019s choice in relapsed\/refractory chronic lymphocytic leukemia: final ASCEND trial results","volume":"6","author":"Ghia P","year":"2022","unstructured":"Ghia P, Pluta A, Wach M,  Acalabrutinib versus investigator\u2019s choice in relapsed\/refractory chronic lymphocytic leukemia: final ASCEND trial results. Hemasphere 2022;6:e801."},{"key":"B23","series-title":"Leukemia","first-page":"532","article-title":"Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia","volume":"36","author":"Castillo JJ","year":"2022","unstructured":"Castillo JJ, Meid K, Gustine JN,  Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia. Leukemia 2022;36:532\u2013539."},{"key":"B24","series-title":"J Clin Oncol","first-page":"5099","article-title":"Zanubrutinib versus ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: final analysis from the randomized phase III ASPEN study","volume":"41","author":"Dimopoulos MA","year":"2023","unstructured":"Dimopoulos MA, Opat S, D\u2019Sa S,  Zanubrutinib versus ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: final analysis from the randomized phase III ASPEN study. J Clin Oncol 2023;41:5099\u20135106."},{"key":"B25","series-title":"Lancet Haematol","first-page":"e112","article-title":"Acalabrutinib monotherapy in patients with Waldenstr\u00f6m macroglobulinemia: a single-arm, multicentre, phase 2 study","volume":"7","author":"Owen RG","year":"2020","unstructured":"Owen RG, McCarthy H, Rule S,  Acalabrutinib monotherapy in patients with Waldenstr\u00f6m macroglobulinemia: a single-arm, multicentre, phase 2 study. Lancet Haematol 2020;7:e112\u2013121."},{"key":"B26","series-title":"Haematologica","first-page":"e211","article-title":"Ibrutinib for the treatment of relapsed\/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis","volume":"104","author":"Rule S","year":"2019","unstructured":"Rule S, Dreyling M, Goy A,  Ibrutinib for the treatment of relapsed\/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis. Haematologica 2019;104:e211\u2013214."},{"key":"B27","series-title":"Blood","first-page":"3148","article-title":"Zanubrutinib in relapsed\/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study","volume":"139","author":"Song Y","year":"2022","unstructured":"Song Y, Zhou K, Zou D,  Zanubrutinib in relapsed\/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study. Blood 2022;139:3148\u20133158."},{"key":"B28","series-title":"Lancet","first-page":"659","article-title":"Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial","volume":"391","author":"Wang M","year":"2018","unstructured":"Wang M, Rule S, Zinzani PL,  Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet 2018;391:659\u2013667."},{"key":"B29","series-title":"Blood Adv","first-page":"5773","article-title":"Durable ibrutinib responses in relapsed\/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis","volume":"4","author":"Noy A","year":"2020","unstructured":"Noy A, de Vos S, Coleman M,  Durable ibrutinib responses in relapsed\/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis. Blood Adv 2020;4:5773\u20135784."},{"key":"B30","series-title":"Br J Haematol","first-page":"76","article-title":"A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma","volume":"199","author":"Strati P","year":"2022","unstructured":"Strati P, Coleman M, Champion R,  A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma. Br J Haematol 2022;199:76\u201385."},{"key":"B31","series-title":"Clin Cancer Res","first-page":"3586","article-title":"FDA Approval: ibrutinib for patients with previously treated mantle cell lymphoma and previously treated chronic lymphocytic leukemia","volume":"21","author":"de Claro RA","year":"2015","unstructured":"de Claro RA, McGinn KM, Verdun N,  FDA Approval: ibrutinib for patients with previously treated mantle cell lymphoma and previously treated chronic lymphocytic leukemia. Clin Cancer Res 2015;21:3586\u20133590."},{"key":"B32","series-title":"Bioorg Med Chem","first-page":"116358","article-title":"Progress in the development of small molecular inhibitors of the Bruton\u2019s tyrosine kinase (BTK) as a promising cancer therapy","volume":"47","author":"Liu XJ","year":"2021","unstructured":"Liu XJ, Xu L, Pang XJ,  Progress in the development of small molecular inhibitors of the Bruton\u2019s tyrosine kinase (BTK) as a promising cancer therapy. Bioorg Med Chem 2021;47:116358."},{"key":"B33","series-title":"Blood Adv","first-page":"1296","article-title":"Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies","volume":"6","author":"Tam CS","year":"2022","unstructured":"Tam CS, Dimopoulos M, Garcia-Sanz R,  Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies. Blood Adv 2022;6:1296\u20131308."},{"key":"B34","series-title":"Blood Adv","first-page":"3531","article-title":"Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma","volume":"7","author":"Tatarczuch M","year":"2023","unstructured":"Tatarczuch M, Waltham M, Shortt J,  Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma. Blood Adv 2023;7:3531\u20133539."},{"key":"B35","series-title":"Nat Med","first-page":"87","article-title":"Pharmacological and genomic profiling identifies NF-\u03baB-targeted treatment strategies for mantle cell lymphoma","volume":"20","author":"Rahal R","year":"2014","unstructured":"Rahal R, Frick M, Romero R,  Pharmacological and genomic profiling identifies NF-\u03baB-targeted treatment strategies for mantle cell lymphoma. Nat Med 2014;20:87\u201392."},{"key":"B36","series-title":"Nat Med","first-page":"1662","article-title":"Detection of early seeding of Richter transformation in chronic lymphocytic leukemia","volume":"28","author":"Nadeu F","year":"2022","unstructured":"Nadeu F, Royo R, Massoni-Badosa R,  Detection of early seeding of Richter transformation in chronic lymphocytic leukemia. Nat Med 2022;28:1662\u20131671."},{"key":"B37","series-title":"Cancer","first-page":"559","article-title":"Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation","volume":"125","author":"Kanagal-Shamanna R","year":"2019","unstructured":"Kanagal-Shamanna R, Jain P, Patel KP,  Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation. Cancer 2019;125:559\u2013574."},{"key":"B38","series-title":"Blood","first-page":"1061","article-title":"Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib","volume":"144","author":"Woyach JA","year":"2024","unstructured":"Woyach JA, Jones D, Jurczak W,  Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib. Blood 2024;144:1061\u20131068."},{"key":"B39","series-title":"N Engl J Med","first-page":"33","article-title":"Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia","volume":"389","author":"Mato AR","year":"2023","unstructured":"Mato AR, Woyach JA, Brown JR,  Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia. N Engl J Med 2023;389:33\u201344."},{"key":"B40","series-title":"J Hematol Oncol","first-page":"96","article-title":"Predictive factors and outcomes for ibrutinib in relapsed\/refractory marginal zone lymphoma: a multicenter cohort study","volume":"15","author":"Epperla N","year":"2022","unstructured":"Epperla N, Zhao Q, Chowdhury SM,  Predictive factors and outcomes for ibrutinib in relapsed\/refractory marginal zone lymphoma: a multicenter cohort study. J Hematol Oncol 2022;15:96."},{"key":"B41","series-title":"Blood Adv","first-page":"88","article-title":"Postibrutinib relapse outcomes for patients with marginal zone lymphoma","volume":"7","author":"Epperla N","year":"2023","unstructured":"Epperla N, Zhao Q, Chowdhury SM,  Postibrutinib relapse outcomes for patients with marginal zone lymphoma. Blood Adv 2023;7:88\u201391."},{"key":"B42","series-title":"Drugs","first-page":"547","article-title":"Pirtobrutinib: first approval","volume":"83","author":"Keam SJ","year":"2023","unstructured":"Keam SJ. Pirtobrutinib: first approval. Drugs 2023;83:547\u2013553."},{"key":"B43","series-title":"Lancet","first-page":"892","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study","volume":"397","author":"Mato AR","year":"2021","unstructured":"Mato AR, Shah NN, Jurczak W,  Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study. Lancet 2021;397:892\u2013901."},{"key":"B44","series-title":"Blood","first-page":"7004","article-title":"Efficacy and safety of nemtabrutinib, a wild-type and C481S-mutated Bruton tyrosine kinase inhibitor for B-cell malignancies: updated analysis of the open-label phase 1\/2 dose-expansion Bellwave-001 study","volume":"140","author":"Woyach JA","year":"2022","unstructured":"Woyach JA, Flinn IW, Awan FT,  Efficacy and safety of nemtabrutinib, a wild-type and C481S-mutated Bruton tyrosine kinase inhibitor for B-cell malignancies: updated analysis of the open-label phase 1\/2 dose-expansion Bellwave-001 study. Blood 2022;140(Suppl 1):7004\u20137006."},{"key":"B45","series-title":"Biomark Res","first-page":"17","article-title":"Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma","volume":"10","author":"Zhang J","year":"2022","unstructured":"Zhang J, Lu X, Li J,  Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma. Biomark Res 2022;10:17."},{"key":"B46","series-title":"Blood Cancer J","first-page":"39","article-title":"Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication","volume":"11","author":"Lu P","year":"2021","unstructured":"Lu P, Wang S, Franzen CA,  Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication. Blood Cancer J 2021;11:39."},{"key":"B47","series-title":"Biochemistry","first-page":"3564","article-title":"Targeting the C481S ibrutinib-resistance mutation in Bruton\u2019s tyrosine kinase using PROTAC-mediated degradation","volume":"57","author":"Buhimschi AD","year":"2018","unstructured":"Buhimschi AD, Armstrong HA, Toure M,  Targeting the C481S ibrutinib-resistance mutation in Bruton\u2019s tyrosine kinase using PROTAC-mediated degradation. Biochemistry 2018;57:3564\u20133575."},{"key":"B48","series-title":"Cell Res","first-page":"779","article-title":"PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies","volume":"28","author":"Sun Y","year":"2018","unstructured":"Sun Y, Zhao X, Ding N,  PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies. Cell Res 2018;28:779\u2013781."},{"key":"B49","series-title":"Leukemia","first-page":"2105","article-title":"Degradation of Bruton\u2019s tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas","volume":"33","author":"Sun Y","year":"2019","unstructured":"Sun Y, Ding N, Song Y,  Degradation of Bruton\u2019s tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas. Leukemia 2019;33:2105\u20132110."},{"key":"B50","series-title":"Blood","first-page":"4504","article-title":"MYD88 L265P mutation in Waldenstrom macroglobulinemia","volume":"121","author":"Poulain S","year":"2013","unstructured":"Poulain S, Roumier C, Decambron A,  MYD88 L265P mutation in Waldenstrom macroglobulinemia. Blood 2013;121:4504\u20134511."},{"key":"B51","series-title":"Br J Haematol","first-page":"356","article-title":"CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenstr\u00f6m macroglobulinaemia treated with ibrutinib","volume":"187","author":"Castillo JJ","year":"2019","unstructured":"Castillo JJ, Xu L, Gustine JN,  CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenstr\u00f6m macroglobulinaemia treated with ibrutinib. Br J Haematol 2019;187:356\u2013363."},{"key":"B52","series-title":"N Engl J Med","first-page":"2305","article-title":"BRAF mutations in hairy-cell leukemia","volume":"364","author":"Tiacci E","year":"2011","unstructured":"Tiacci E, Trifonov V, Schiavoni G,  BRAF mutations in hairy-cell leukemia. N Engl J Med 2011;364:2305\u20132315."},{"key":"B53","series-title":"Blood","first-page":"732","article-title":"Genetic and phenotypic attributes of splenic marginal zone lymphoma","volume":"139","author":"Bonfiglio F","year":"2022","unstructured":"Bonfiglio F, Bruscaggin A, Guidetti F,  Genetic and phenotypic attributes of splenic marginal zone lymphoma. Blood 2022;139:732\u2013747."},{"key":"B54","series-title":"N Engl J Med","first-page":"568","article-title":"Marginal-zone lymphomas","volume":"386","author":"Rossi D","year":"2022","unstructured":"Rossi D, Bertoni F, Zucca E. Marginal-zone lymphomas. N Engl J Med 2022;386:568\u2013581."},{"key":"B55","series-title":"Clin Cancer Res","first-page":"4174","article-title":"Genetics and prognostication in splenic marginal zone lymphoma: revelations from deep sequencing","volume":"21","author":"Parry M","year":"2015","unstructured":"Parry M, Rose-Zerilli MJ, Ljungstr\u00f6m V,  Genetics and prognostication in splenic marginal zone lymphoma: revelations from deep sequencing. Clin Cancer Res 2015;21:4174\u20134183."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/23\/7\/article-e257045.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/23\/7\/article-e257045.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/23\/7\/article-e257045.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T12:30:11Z","timestamp":1752150611000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/23\/7\/article-e257045.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":55,"journal-issue":{"issue":"7"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2025.7045","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}